
Global GPCR Agonist Market Size, Trends and Growth Opportunity, By Product Type (Instruments, Reagents and Chemicals, and Kits), By Technology (High-Throughput Functional Cell Based Assay, Fluorescence Microscopy Analysis, Triple-Quadrupole Mass Spectrosc
Description
Global GPCR Agonist Market Size, Trends and Growth Opportunity, By Product Type(Instruments, Reagents and Chemicals, and Kits), By Technology (High-Throughput Functional Cell Based Assay, Fluorescence Microscopy Analysis, Triple-Quadrupole Mass Spectroscopy, Luciferaase Assay, Real-Time Bioluminescence, Resource Energy Transfer (Bret) Assay, Reporter Gene Assay, Camp Assay, Cgmp Assay, and High Thtroughput Screening (HTS) Assay), By Application(Cancer Research, Cardiovascular System Diseases, Central Nervous System Diseases, Drug Discovery, and Others), By End-Use Industry (Academic Institutes and Research Institutes, Clinical Research Organizations, and Biophrmaceutical Companies), By Region and Forecast Till 2027.
Global GPCR Agonist Market
Global GPCR Agonist Market was valued at USD 2.5 billion in 2021, which is expected to reach USD 11.7 billion by 2027, with 20.91% CAGR from 2022 to 2027.
GPCR antagonists, also known as protein-coupled receptors, play a significant role in pathways that are relevant to medicine. These are used to treat a variety of illnesses, including circulatory system ailments, autoimmune diseases, and diseases of the central nervous system (CNS). Additionally, GPCR agonists are utilized to treat CNS conditions like Alzheimer's, Parkinson's, and Huntington's disease, which are prevalent in the elderly population.
Market Drivers
The global GPCR agonist market is anticipated to develop as the prevalence of various disorders such as cancer, autoimmune diseases, and Central Nervous System Diseases (CNS) rises. Additionally, an improvement in the efficiency of identifying pharmaceutically relevant drug candidates is anticipated to fuel the expansion of the worldwide GPCR agonist market. Additionally, throughout this projection period, research and development in drug discovery is anticipated to drive the growth of the worldwide GPCR agonist market. Additionally, an increase in allosteric modules, biased diagnostics, and the use of biological therapies will spur demand for GPCR agonists globally.
Market Restraints
Low abundance, poor stability, and structural plasticity leading to various conformations are some of the characteristics that make it difficult to purify GPCRs. Despite this, a number of non-rhodopsin GPCR structures have been determined from purified proteins utilizing a generally comparable approach of one or more affinity stages. These elements could impede market expansion.
Market Segmentation
Global GPCR Agonist market is segmented into product type, technology, application and end user. By product type it is segmented into instruments (microfluidicdroplet generator, single-inlet microfluidic device, air compressor, micromanipulator, confocal microscope, mitos-p-pump, and microplate fluorometer), reagents and chemicals (cell line, repoter gene, and media), and kits. By technology it is segmented into high-throughput functional cell based assay, fluorescence microscopy analysis, triple-quadrupole mass spectroscopy, luciferaase assay, real-time bioluminescence, resource energy transfer (bret) assay, reporter gene assay, camp assay, cgmp assay, and high thtroughput screening (hts) assay. By application it is segmented into cancer research, cardiovascular system diseases, central nervous system diseases, drug discovery, and others. By end user it is segmented into academic institutes and research institutes, clinical research organizations, and biophrmaceutical companies.
Regional Analysis
The GPCR Agonist market segmented into five regions North America, Europe, Latin America, Asia Pacific, Middle East and Africa. The Asia-Pacific region is anticipated to expand significantly over the course of the forecast period due to the region's unfulfilled market needs, rising per capita income, and the economic development of nations like China and India, as well as rising government investment in the biotechnology and biopharmaceutical sector.
Market Key Players
Various key players are discussed in this report such as European Collection of Cell Culture, Clontech Laboratries, Inc.,Nacalai Tesque, GE Healthcare, Thermo Fisher Scientific, Nano-Glo™ Luciferase Assay System, Promega, Fluoroskan Ascent, Sigma-Aldrich, Wako Pure Chemical Industries, Zymo Research, Clontech Laboratries, Inc.,and Drummond Scientific Co.
Market Taxonomy
By Product Type
Global GPCR Agonist Market
Global GPCR Agonist Market was valued at USD 2.5 billion in 2021, which is expected to reach USD 11.7 billion by 2027, with 20.91% CAGR from 2022 to 2027.
GPCR antagonists, also known as protein-coupled receptors, play a significant role in pathways that are relevant to medicine. These are used to treat a variety of illnesses, including circulatory system ailments, autoimmune diseases, and diseases of the central nervous system (CNS). Additionally, GPCR agonists are utilized to treat CNS conditions like Alzheimer's, Parkinson's, and Huntington's disease, which are prevalent in the elderly population.
Market Drivers
The global GPCR agonist market is anticipated to develop as the prevalence of various disorders such as cancer, autoimmune diseases, and Central Nervous System Diseases (CNS) rises. Additionally, an improvement in the efficiency of identifying pharmaceutically relevant drug candidates is anticipated to fuel the expansion of the worldwide GPCR agonist market. Additionally, throughout this projection period, research and development in drug discovery is anticipated to drive the growth of the worldwide GPCR agonist market. Additionally, an increase in allosteric modules, biased diagnostics, and the use of biological therapies will spur demand for GPCR agonists globally.
Market Restraints
Low abundance, poor stability, and structural plasticity leading to various conformations are some of the characteristics that make it difficult to purify GPCRs. Despite this, a number of non-rhodopsin GPCR structures have been determined from purified proteins utilizing a generally comparable approach of one or more affinity stages. These elements could impede market expansion.
Market Segmentation
Global GPCR Agonist market is segmented into product type, technology, application and end user. By product type it is segmented into instruments (microfluidicdroplet generator, single-inlet microfluidic device, air compressor, micromanipulator, confocal microscope, mitos-p-pump, and microplate fluorometer), reagents and chemicals (cell line, repoter gene, and media), and kits. By technology it is segmented into high-throughput functional cell based assay, fluorescence microscopy analysis, triple-quadrupole mass spectroscopy, luciferaase assay, real-time bioluminescence, resource energy transfer (bret) assay, reporter gene assay, camp assay, cgmp assay, and high thtroughput screening (hts) assay. By application it is segmented into cancer research, cardiovascular system diseases, central nervous system diseases, drug discovery, and others. By end user it is segmented into academic institutes and research institutes, clinical research organizations, and biophrmaceutical companies.
Regional Analysis
The GPCR Agonist market segmented into five regions North America, Europe, Latin America, Asia Pacific, Middle East and Africa. The Asia-Pacific region is anticipated to expand significantly over the course of the forecast period due to the region's unfulfilled market needs, rising per capita income, and the economic development of nations like China and India, as well as rising government investment in the biotechnology and biopharmaceutical sector.
Market Key Players
Various key players are discussed in this report such as European Collection of Cell Culture, Clontech Laboratries, Inc.,Nacalai Tesque, GE Healthcare, Thermo Fisher Scientific, Nano-Glo™ Luciferase Assay System, Promega, Fluoroskan Ascent, Sigma-Aldrich, Wako Pure Chemical Industries, Zymo Research, Clontech Laboratries, Inc.,and Drummond Scientific Co.
Market Taxonomy
By Product Type
- Instruments
- Microfluidic droplet generator
- Single-inlet microfluidic device
- Air compressor
- Micromanipulator
- Confocal microscope
- Mitos P-Pump
- Microplate Fluorometer
- Reagents and chemicals
- Cell line
- Repoter gene
- Media
- Kits
- High-Throughput Functional Cell-Based Assay
- Fluorescence Microscopy Analysis
- Triple-quadrupole mass spectrometry
- Luciferase Assay
- Real-Time Bioluminescence Resonance Energy Transfer (BRET) Assay
- Reporter gene assay
- cAMP assay
- cGMP assay
- High Throughput Screening (HTS) Assay
- Cancer research
- Cardiovascular System diseases
- Central Nervous System (CNS) diseases
- Immune System diseases
- Other Therapeutic Areas
- Drug discovery
- Academic Institutes And Research Institutes
- Clinical Research Organizations
- Biopharmaceutical Companies
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
- What are the Key Opportunities in Global GPCR Agonist Market?
- What will be the growth rate from 2022 to 2027?
- Which segment/region will have highest growth?
- What are the factors that will impact/drive the Market?
- What is the role of key players in the value chain?
Table of Contents
147 Pages
- 1.Executive Summary
- 1.1.Market Taxonomy
- 2.Global GPCR Agonist Market Demand (in Value or Size in US$ Mn) Analysis and Forecast
- 3. Market Background
- 3.1.Forecast Factor
- 3.2. Market Dynamics
- 3.2.1.Drivers
- 3.2.2.Challenges
- 3.2.3.Trends
- 4.Global GPCR Agonist Market Snapshot
- 5.Global GPCR Agonist Market Analysis, By Product Type
- 5.1.Y-o-Y Growth Comparison, By Product Type
- 5.2.Global GPCR Agonist Market Share Analysis, By Product Type
- 5.3.Global GPCR Agonist Market Size and Forecast, By Product Type
- 5.3.1 Instruments
- 5.3.1.1 Microfluidic droplet generator
- 5.3.1.2 Single –inlet microfludic device
- 5.3.1.3 Air Compressor
- 5.3.1.4Micromanipulator
- 5.3.1.5Confocal Microscope
- 5.3.1.6Mitos p pump
- 5.3.1.7Microplate Fluoremeter
- 5.3.2 Reagents and Chemicals
- 5.3.2.1 Cell Line
- 5.3.2.2 Repoter gene
- 5.3.2.3 Media
- 5.3.3 Kit
- 6.Global GPCR Agonist Market Analysis, By Technology
- 6.1.Y-o-Y Growth Comparison, By Technology
- 6.2.Global GPCR Agonist Market Share Analysis, By Technology
- 6.3. Global GPCR Agonist Market Size and Forecast, By Technology
- 6.3.1High Throughput Functional Cell Based Assay
- 6.3.2 Fluorescence Microscopy Analysis
- 6.3.3 Triple-quadrupole mass spectroscopy
- 6.3.4 Luciferase Assay
- 6.3.5 Real Time Bioluminescence Resonance Energy Transfer (BRET) Assay
- 6.3.6 Reporter Gene Assay
- 6.3.7 cAMP Assay
- 6.3.8 cGMP Assay
- 6.3.9 High Throughput Screening (HTS) Assay
- 7.Global GPCR Agonist Market Analysis, By Application
- 7.1.Y-o-Y Growth Comparison, By Application
- 7.2.Global GPCR Agonist Market Share Analysis, By Application
- 7.3.Global GPCR Agonist Market Size and Forecast, By Application
- 7.3.1 Cancer Research
- 7.3.2 Cardiovascular System Diseases
- 7.3.3 Central Nervous System (CNS) Diseases
- 7.3.4 Immune System Diseases
- 7.3.5 Other Therapeutic Areas
- 7.3.6 Drug Discovery
- 8.Global GPCR Agonist Market Analysis, By End User
- 8.1.Y-o-Y Growth Comparison, By End User
- 8.2.Global GPCR Agonist Market Share Analysis, By End User
- 8.3. Global GPCR Agonist Market Size and Forecast, By End User
- 8.3.1 Academic Institutes & Research institutes
- 8.3.2 Clinical Research Organizations
- 8.3.3 Biopharmaceutical Companies
- 9.Global GPCR Agonist Market Analysis, By Region
- 9.1.Y-o-Y Growth Comparison, By Region
- 9.2.Global GPCR Agonist Market Share Analysis, By Region
- 10.North America GPCR Agonist Market Analysis and Forecast (2022-2027)
- 10.1 Introduction
- 10.2 North America GPCR Agonist Market Analysis, By Product Type
- 10.3 North America GPCR Agonist Market Analysis, By Technology
- 10.4 North America GPCR Agonist Market Analysis, By Application
- 10.5 North America GPCR Agonist Market Analysis, By End User
- 10.6 North America GPCR Agonist Market Analysis, By Country
- 10.6.1USA
- 10.6.2 Canada
- 10.6.3 Mexico
- 11. Europe GPCR Agonist Market Analysis and Forecast (2022-2027)
- 11.1 Introduction
- 11.2 Europe GPCR Agonist Market Analysis, By Product Type
- 11.3 Europe GPCR Agonist Market Analysis, By Technology
- 11.4 Europe GPCR Agonist Market Analysis, By Application
- 11.5 Europe GPCR Agonist Market Analysis, By End User
- 11.6 Europe GPCR Agonist Market Analysis, By Country
- 11.6.1Germany
- 11.6.2 France
- 11.6.3 UK
- 11.6.4 Rest of Europe
- 12. Asia Pacific GPCR Agonist Market Analysis and Forecast (2022-2027)
- 12.1 Introduction
- 12.2 Asia Pacific GPCR Agonist Market Analysis, By Product Type
- 12.3 Asia Pacific GPCR Agonist Market Analysis, By Technology
- 12.4 Asia Pacific GPCR Agonist Market Analysis, By Application
- 12.5 Asia Pacific GPCR Agonist Market Analysis, By End User
- 12.6 Asia Pacific GPCR Agonist Market Analysis, By Country
- 12.6.1China
- 12.6.2 India
- 12.6.3 Japan
- 12.6.4 Rest of Asia Pacific
- 13. Latin America GPCR Agonist Market Analysis and Forecast (2022-2027)
- 13.1 Introduction
- 13.2 Latin America GPCR Agonist Market Analysis, By Product Type
- 13.3 Latin America GPCR Agonist Market Analysis, By Technology
- 13.4 Latin America GPCR Agonist Market Analysis, By Application
- 13.54 Latin America GPCR Agonist Market Analysis, By End User
- 14. Middle East & Africa GPCR Agonist Market Analysis and Forecast (2022-2027)
- 14.1 Introduction
- 14.2 Middle East & Africa GPCR Agonist Market Analysis, By Product Type
- 14.3 Middle East & Africa GPCR Agonist Market Analysis, By Technology
- 14.4 Middle East & Africa GPCR Agonist Market Analysis, By Application
- 14.5 Middle East & Africa GPCR Agonist Market Analysis, By End User
- 15.Competition Analysis
- 15.1 Competition Dashboard
- 15.2 Market Share Analysis of Top Vendors
- 15.3 Key Development Strategies
- 16. Company Profiles
- 16.1 European Collection of Cell Culture
- 16.1.1 Overview
- 16.1.2 Offerings
- 16.1.3 Key Financial
- 16.1.4 Business Segment & Geographic Overview
- 16.1.5 Key Market Developments
- 16.1.6 Key Strategies
- 16.2 Clontech Laboratries, Inc.
- 16.2.1 Overview
- 16.2.2 Offerings
- 16.2.3 Key Financial
- 16.2.4 Business Segment & Geographic Overview
- 16.2.5 Key Market Developments
- 16.2.6 Key Strategies
- 16.3 Nacalai Tesque
- 16.3.1 Overview
- 16.3.2 Offerings
- 16.3.3 Key Financial
- 16.3.4 Business Segment & Geographic Overview
- 16.3.5 Key Market Developments
- 16.3.6 Key Strategies
- 16.4 GE Healthcare
- 16.4.1 Overview
- 16.4.2 Offerings
- 16.4.3 Key Financial
- 16.4.4 Business Segment & Geographic Overview
- 16.4.5 Key Market Developments
- 16.4.6 Key Strategies
- 16.5 Thermo Fisher Scientific
- 16.5.1 Overview
- 16.5.2 Offerings
- 16.5.3 Key Financial
- 16.5.4 Business Segment & Geographic Overview
- 16.5.5 Key Market Developments
- 16.5.6 Key Strategies
- 16.6 Nano-Glo™
- 16.7 Luciferase Assay System
- 16.7.1 Overview
- 16.7.2 Offerings
- 16.7.3 Key Financial
- 16.7.4 Business Segment & Geographic Overview
- 16.7.5 Key Market Developments
- 16.7.6 Key Strategies
- 16.8 Promega
- 16.8.1 Overview
- 16.8.2 Offerings
- 16.8.3 Key Financial
- 16.8.4 Business Segment & Geographic Overview
- 16.8.5 Key Market Developments
- 16.8.6 Key Strategies
- 16.9 Ascent, Sigma-Aldrich
- 16.9.1 Overview
- 16.9.2 Offerings
- 16.9.3 Key Financial
- 16.9.4 Business Segment & Geographic Overview
- 16.9.5 Key Market Developments
- 16.9.6 Key Strategies
- 16.10 Wako Pure Chemical Industries
- 16.10.1 Overview
- 16.10.2 Offerings
- 16.10.3 Key Financial
- 16.10.4 Business Segment & Geographic Overview
- 16.10.5 Key Market Developments
- 16.10.6 Key Strategies
- Others
- 16.11 Zymo Research
- 16.12 Clontech Laboratries, Inc
- 16.13 Drummond Scientific Co
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.